Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Oldgren, Jonas; Laurila, Sanna; Åkerblom, Axel; Latva‐Rasku, Aino; Rebelos, Eleni; Isackson, Henrik; Saarenhovi, Maria; Eriksson, Olof; Heurling, Kerstin; Johansson, Edvin; Wilderäng, Ulrica; Karlsson, Cecilia; Esterline, Russell; Ferrannini, Ele; Oscarsson, Jan; Nuutila, Pirjo

doi:10.1111/dom.14363

Public

Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study

Published in Diabetes Obesity and Metabolism • Feb 24, 2021

Authors:

Jonas Oldgren

Sanna Laurila

Axel Åkerblom

Abstract

Abstract Aim To explore the early effects of dapagliflozin on myocardial function and metabolism in patients with type 2 diabetes without heart failure. Materials and Methods Patients with type 2 diabetes on metformin treatment were randomized to double‐blind, 6‐week placebo or dapagliflozin 10 mg d...

Subject

Dapagliflozin

Medicine

Type 2 diabetes

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!